Seer to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Rhea-AI Summary

Seer (Nasdaq: SEER) will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. Management will host a live webcast and conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Live audio and an archived replay will be available on the company investor website.

News Market Reaction – SEER

+2.29% 2.2x vol

1 alert

+2.29% News Effect

+$2M Valuation Impact

$102M Market Cap

2.2x Rel. Volume

On the day this news was published, SEER gained 2.29%, reflecting a moderate positive market reaction. This price movement added approximately $2M to the company's valuation, bringing the market cap to $102M at that time. Trading volume was elevated at 2.2x the daily average, suggesting notable buying interest.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Earnings date: February 26, 2026 Earnings call time: 1:30 p.m. PT / 4:30 p.m. ET

2 metrics

Earnings date February 26, 2026 Q4 and full-year 2025 results release

Earnings call time 1:30 p.m. PT / 4:30 p.m. ET Scheduled webcast conference call

Market Reality Check

Price: $1.98 Vol: Volume 316,479 is 2.17x t...

high vol

$1.98 Last Close

Volume Volume 316,479 is 2.17x the 20-day average of 145,725. high

Technical Price 1.81 is trading below the 200-day MA of 2.05 and nearer the 52-week low of 1.62 than the high of 2.41.

Peers on Argus

SEER is up 1.12% while key biotech peers like KALA (-7.16%), ADAG (-4.7%), CGEN ...

SEER is up 1.12% while key biotech peers like KALA (-7.16%), ADAG (-4.7%), CGEN (-3.33%), IOBT (-2.02%), and FBIO (-1.28%) are down, pointing to stock-specific dynamics rather than a sector-wide move.

Historical Context

5 past events · Latest: Dec 01 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 01	Platform validation	Positive	-1.0%	Nature Genetics study validated Proteograph platform and identified novel pQTL signals.
Nov 07	Scientific presentations	Positive	-3.2%	HUPO 2025 data showcased Proteograph use across multiple disease and biology areas.
Nov 06	Q3 2025 earnings	Positive	-0.5%	Q3 2025 results with higher revenue, improved loss, and reiterated 2025 guidance.
Oct 29	Investor conferences	Neutral	-3.1%	Planned participation in UBS and Canaccord investor conferences with webcasts.
Oct 16	Earnings date	Neutral	-2.3%	Announcement of Q3 2025 earnings date and webcast timing on Nov 6, 2025.

Pattern Detected

Recent news, including positive scientific validation and financial updates, has often been followed by negative next-day price reactions.

Recent Company History

This announcement schedules SEER’s Q4 and full-year 2025 earnings call for Feb 26, 2026, consistent with prior communication patterns. Over the last several months, SEER highlighted external validation of its Proteograph platform in a Nov 2025 Nature Genetics study and showcased broad translational proteomics data at HUPO 2025. Financially, it reported Q3 2025 revenue of $4.1 million with reiterated full-year guidance and participated in multiple investor conferences. A prior Q3 2025 earnings-date announcement on Nov 6, 2025 was also paired with a webcast, mirroring today’s setup.

Market Pulse Summary

This announcement schedules SEER’s Q4 and full-year 2025 results and webcast, continuing its practic...

Analysis

This announcement schedules SEER’s Q4 and full-year 2025 results and webcast, continuing its practice of pre-announcing earnings dates and investor access details. In recent months, the company reported Q3 2025 revenue of $4.1 million with reiterated full-year guidance and highlighted external validation of its Proteograph platform. Investors following this update may watch the forthcoming call for trends in revenue growth, cash usage, and how new scientific data translate into commercial progress.

Key Terms

proteomic

1 terms

proteomic medical

"the pioneer and trusted partner for deep, unbiased proteomic insights, today announced"

Proteomic describes something related to the large-scale study of proteins—the working parts inside cells that carry out functions and signal changes. For investors, proteomic work can reveal new drug targets, diagnostic tests or biomarkers that change a company’s potential revenue and risk profile; think of it like analyzing all ingredients in a recipe to find which ones can be improved or swapped to make a better product.

AI-generated analysis. Not financial advice.

REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the fourth quarter and full year 2025 on Thursday, February 26, 2026. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the event.

About Seer
Seer is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph™ Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.

Media Contact:
Patrick Schmidt
pr@seer.bio 

Investor Contact:
investor@seer.bio 

FAQ

When will Seer (SEER) report Q4 and full year 2025 financial results?

Seer will report results on Thursday, February 26, 2026, with a management webcast and call starting at 1:30 p.m. PT / 4:30 p.m. ET. According to the company, the event will cover fourth quarter and full year 2025 financial results and commentary.

How can investors listen to Seer (SEER) earnings call on February 26, 2026?

Investors can listen via live audio webcast on Seer’s investor website at investor.seer.bio. According to the company, a live webcast will stream at the scheduled time and an archived replay will be posted afterwards for on-demand access.

What time is Seer (SEER) management’s conference call for the Q4 2025 release?

The conference call begins at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on February 26, 2026. According to the company, management will webcast the call and provide a subsequent archived replay on its investor site.

Will Seer (SEER) make a replay of the February 26, 2026 webcast available?

Yes. An archived replay will be available on Seer’s investor website after the live event. According to the company, the replay will be posted on the company website following the webcast for later review.